Roche: cancer drug Polivy approved in Canada
(CercleFinance.com) - Roche announced on Thursday that the Canadian health authorities have approved the commercialisation of Polivy in the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL).
The authorisation given by Health Canada concerns the use of the drug in combination with two other anti-cancer drugs - bendamustine and rituximab - in patients who are not eligible for stem cell transplantation and have previously received at least one therapy.
Patients with diffuse large B-cell lymphoma, an aggressive form of non-Hodgkin's lymphoma, usually respond favourably to treatment, although 40% do not recover or relapse, This limits their treatment options and increases the risk of death.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The authorisation given by Health Canada concerns the use of the drug in combination with two other anti-cancer drugs - bendamustine and rituximab - in patients who are not eligible for stem cell transplantation and have previously received at least one therapy.
Patients with diffuse large B-cell lymphoma, an aggressive form of non-Hodgkin's lymphoma, usually respond favourably to treatment, although 40% do not recover or relapse, This limits their treatment options and increases the risk of death.
Copyright (c) 2020 CercleFinance.com. All rights reserved.